Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-11
2011-12-06
Berch, Mark (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S263200, C514S263220, C536S027610, C544S277000, C548S376100
Reexamination Certificate
active
08071565
ABSTRACT:
Compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, R1, R2and R3have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2Areceptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
REFERENCES:
patent: 4008125 (1977-02-01), Kurozumi et al.
patent: 4738954 (1988-04-01), Hamilton et al.
patent: 4873360 (1989-10-01), Johnson et al.
patent: 4954504 (1990-09-01), Chen et al.
patent: 5688774 (1997-11-01), Jacobson et al.
patent: 6307054 (2001-10-01), Truesdale et al.
patent: 6376472 (2002-04-01), Myers et al.
patent: 6403567 (2002-06-01), Zablocki et al.
patent: 6429315 (2002-08-01), Sledeski et al.
patent: 6492348 (2002-12-01), Bays et al.
patent: 6559313 (2003-05-01), Myers et al.
patent: 6677316 (2004-01-01), Bays et al.
patent: 7553823 (2009-06-01), Zablocki et al.
patent: 7737126 (2010-06-01), Blatcher et al.
patent: 2003/0092668 (2003-05-01), Liang et al.
patent: 2003/0176390 (2003-09-01), Herling et al.
patent: 2004/0106572 (2004-06-01), Fishman et al.
patent: 2004/0162422 (2004-08-01), Hall et al.
patent: 2005/0101551 (2005-05-01), Sevillano et al.
patent: 2005/0182018 (2005-08-01), Linden et al.
patent: 2006/0142237 (2006-06-01), Fishman et al.
patent: 2006/0189636 (2006-08-01), Critchley et al.
patent: 2007/0099865 (2007-05-01), Fishman et al.
patent: 2007/0191293 (2007-08-01), Langston et al.
patent: 2007/0232626 (2007-10-01), Jacobson et al.
patent: 2008/0027022 (2008-01-01), Linden et al.
patent: 2008/0051364 (2008-02-01), Fishman et al.
patent: 2008/0051404 (2008-02-01), Claiborne et al.
patent: 2008/0200483 (2008-08-01), Fairhurst et al.
patent: 2008/0207648 (2008-08-01), Fairhurst et al.
patent: 2008/0214581 (2008-09-01), Allen et al.
patent: 2008/0242683 (2008-10-01), Fairhurst et al.
patent: 2008/0262001 (2008-10-01), Kranenburg et al.
patent: 2008/0300213 (2008-12-01), Fishman
patent: 2008/0312160 (2008-12-01), Guerrant et al.
patent: 2009/0012035 (2009-01-01), Jacobson et al.
patent: 2009/0054476 (2009-02-01), Goblyos et al.
patent: 2009/0081764 (2009-03-01), Pausch et al.
patent: 2009/0093633 (2009-04-01), Fairhurst et al.
patent: 2009/0099214 (2009-04-01), Fairhurst et al.
patent: 2009/0105476 (2009-04-01), Fairhurst et al.
patent: 2009/0123510 (2009-05-01), Cronstein et al.
patent: 2009/0181920 (2009-07-01), Watkins et al.
patent: 2009/0181934 (2009-07-01), Fairhurst
patent: 2009/0240045 (2009-09-01), Fairhurst et al.
patent: 2009/0281126 (2009-11-01), Fairhurst et al.
patent: 2009/0281127 (2009-11-01), Fairhurst et al.
patent: 2009/0325967 (2009-12-01), Fairhurst et al.
patent: 2010/0041918 (2010-02-01), Laumen
patent: 2010/0190784 (2010-07-01), Fairhurst et al.
patent: 2010/0197914 (2010-08-01), Fairhurst
patent: 2010/0286126 (2010-11-01), Fairhurst et al.
patent: 0 267 878 (1988-05-01), None
patent: 63-219387 (1988-09-01), None
patent: WO 92/05177 (1992-04-01), None
patent: WO 93/22328 (1993-11-01), None
patent: WO 98/50047 (1998-11-01), None
patent: WO 99/67263 (1999-12-01), None
patent: WO 99/67265 (1999-12-01), None
patent: WO 99/67266 (1999-12-01), None
patent: WO 00/23457 (2000-04-01), None
patent: WO 00/78774 (2000-12-01), None
patent: WO 00/78779 (2000-12-01), None
patent: WO 01/60835 (2001-08-01), None
patent: WO 02/22630 (2002-03-01), None
patent: WO 02/055085 (2002-07-01), None
patent: WO 02/070534 (2002-09-01), None
patent: WO 03/029264 (2003-04-01), None
patent: WO 03/086408 (2003-10-01), None
patent: WO 2005/063246 (2005-07-01), None
patent: WO 2005/084653 (2005-09-01), None
patent: WO 2005/107463 (2005-11-01), None
patent: WO 2005/116037 (2005-12-01), None
patent: WO 2006/011130 (2006-02-01), None
patent: WO 2006/045552 (2006-05-01), None
patent: WO 2006/074925 (2006-07-01), None
patent: WO 2006/097260 (2006-09-01), None
patent: WO 2007/121917 (2007-11-01), None
patent: WO 2007/121919 (2007-11-01), None
patent: WO 2007/121920 (2007-11-01), None
patent: WO 2007/121921 (2007-11-01), None
patent: WO 2007/121923 (2007-11-01), None
patent: WO 2007/121924 (2007-11-01), None
patent: WO 2007/147659 (2007-12-01), None
patent: WO 2008/006563 (2008-01-01), None
Baraldi et al., “Recent improvements in the field of A3 adenosine receptor ligands”, Expert Opinion on Therapeutic Patents, vol. 15, No. 11 (2005), pp. 1507-1519.
Barnard et al., “Inhibition of measles virus replication by 5′-nor carbocyclic adenosine analogues”, Antiviral Chemistry & Chemotherapy, vol. 12, No. 4 (2001), pp. 241-250.
Broadley et al., “Drugs Modulating Adenosine Receptors as Potential Therapeutic Agents for Cardiovascular Diseases”, Expert Opinion on Therapeutic Patents, vol. 10, No. 11 (2000), pp. 1669-1692.
Cowart et al., “Synthesis of Novel Carbocyclic Adenosine Analogues as Inhibitors of Adenosine Kinase”, J. Org. Chem., vol. 64, No. 7 (1999), pp. 2240-2249.
Curran et al., “The Preparation of Optically Active 2, Cyclopenten-1,4-Diol Derivatives from Furfuryl Alcohol”, Tetrahedron, vol. 53, No. 6 (1997), pp. 1983-2004.
Duhamel et al., “Acylation Enatioselective D'un Diol, Meso: Le Cis-Cyclopenthen-2 Diol-1,4”, Tetrahedron Letters, vol. 26, No. 26 (1985), pp. 3099-3102.
Galkina et al., “Studies on an Oixdative, 1,4-Addition to s-trans-1,3-Dienes, a Key Reaction in a Strigol Total Synthesis”, Eur. J. Org. Chem., (2003), pp. 4640-4653.
Ghosh et al. “Synthesis of Enantiomerically Pure 5′-Aza Noraristeromycin Analogs”, J. Org. Chem., vol. 60, No. 18 (1995), pp. 5808-5813.
Hegde et al., “5′-Amino-5′-deoxy-5′-noraristeromycin”, Chemical Abstracts Index entry for Journal of Organic Chemistry, vol. 63, No. 20 (1998), pp. 7092-7094.
Hegde et al., “5′-Amino-5′-deoxy-5′noraristeromycin”, J. Org. Chem., vol. 63, No. 20 (1998), pp. 7092-7094.
Kikugawa et al., “Platelet Aggregation Inhibitors. 6. 12-Thioadenosine Derivatives”, Journal of Medicinal Chemistry, vol. 16, No. 12 (1973), pp. 1381-1388.
Marlene A Jacobsen, “Adenosine receptor agonists”, Expert Opinion Therapeutic Targets, vol. 12, No. 4 (2002), pp. 489-501.
Marumoto et al., “Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines”, Chemical and Pharmaceutical Bulletin, vol. 23, No. 4 (1975), pp. 759-774.
Oriyama et al., “Catalytic Asymmetrization of CIS-2-Cyclopentene-1,4-Diol. Highly Efficient and Practical Synthesis . . .”, Heterocycles, vol. 52, No. 3 (2000), pp. 1055-1069.
Palle et al., “Structure-Affinity Relationships of the Affinity of 2-Pyrazolyl Adenosine Analogues for the Adenosine A2A Receptor”, Bioorganic & Medicinal Chemistry Letters, vol. 12, No. 20 (2002), pp. 2935-2939.
Silverman J, Rheumatol, vol. 35, No. 4(2008), pp. 1-8.
Terashima et al., “Novel Use of Meso-Compound for the Preparation of Optically Active Compounds . . .”, Tetrahedron Letters, vol. 11 (1977), pp. 1001-1004.
Yang et al., “Amino substituted derivatives of 5′-amino-5′-deoxy-5′-noraristeromycin”, Bioorganic & Medicinal Chemistry, vol. 13, No. 3 (2005), pp. 877-882.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 11/576,607, Jan. 11, 2010, 39 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 11/576,607, Dec. 23, 2009, 43 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 11/576,607, Jul. 16, 2010, 40 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 11/722,835, Dec. 22, 2009, 37 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 11/722,835, Jul. 16, 2010, 32 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 12/296,714, Jan. 5, 2010, 4 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 12/296,714, May 19, 2010, 63 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Appl. No. 12/296,714, Dec. 23, 2009, 12 pgs.
Fairhurst, U.S. PTO Office Action, U.S. Ap
Fairhurst Robin Alec
Taylor Roger John
Berch Mark
Novartis AG
Strain Paul D.
Strain & Strain PLLC
LandOfFree
Purine derivatives as a2a agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine derivatives as a2a agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine derivatives as a2a agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315072